The Longevity Biomarkers Panel: What to Test & Track

Medically Reviewed by Dr. Tom Biernacki, DPM, FACFAS | Functional & Longevity Medicine | Updated May 2025

Quick Answer

A longevity biomarkers panel goes far beyond the standard annual physical. It covers metabolic markers (fasting insulin, HOMA-IR, HbA1c), cardiovascular markers (ApoB, Lp(a), hs-CRP, homocysteine), hormonal markers (free T3, testosterone, DHEA-S, IGF-1), nutritional markers (vitamin D, omega-3 index, RBC magnesium), and functional markers (VO2max, HRV, grip strength). Together, these give you a complete biological age picture — not just whether you have a diagnosable disease, but how fast you are aging and where to intervene.

The average annual physical in the United States checks about 12 data points — complete blood count, a basic or comprehensive metabolic panel, TSH, and a standard lipid panel. If everything is within reference range, you are told you are “fine.” I have had patients come to me who were told they were “fine” by that standard who had undetected insulin resistance for a decade, ApoB levels consistent with progressive atherosclerosis, and vitamin D so low it was affecting their muscle function. They were not fine. They were just not yet sick enough for conventional medicine to notice.

A longevity biomarkers panel is not about diagnosing disease. It is about measuring biological age — how fast your systems are aging — and identifying modifiable risk factors years or decades before they become diagnoses. This is the difference between reactive medicine and proactive medicine. In my practice, this panel has changed the clinical picture for the majority of patients who undergo it. Here is what we measure, why each marker matters, and how to interpret what you find.

Why Standard Annual Labs Miss Most of the Picture

Standard labs are designed to diagnose established disease — not to detect its precursors. The reference ranges on your lab report represent the middle 95% of the tested population. In a population where 40% of adults have metabolic syndrome, “population normal” and “biologically optimal” are very different things. A fasting glucose of 98 mg/dL falls within the “normal” reference range, but it can represent years of advancing insulin resistance in the right clinical context. An LDL-C of 118 mg/dL looks acceptable, but an accompanying ApoB of 105 mg/dL tells a very different story about cardiovascular particle burden.

The longevity medicine framework asks a fundamentally different question: not “do you have a diagnosable disease?” but “at what rate are you aging, and what are the levers you can pull to slow that rate?” The biomarkers below answer that question across five domains: metabolic health, cardiovascular risk, hormonal optimization, nutritional sufficiency, and functional capacity.

Metabolic Biomarkers: The Insulin Resistance Picture

Insulin resistance is the most common and most underdiagnosed metabolic disorder in the Western world. It precedes type 2 diabetes by 10-20 years, drives cardiovascular disease, fuels chronic inflammation, and accelerates biological aging through multiple mechanisms. Standard labs catch it only in its late stages. These markers catch it early:

Fasting Insulin

The most sensitive early marker of insulin resistance. The pancreas compensates for early receptor resistance by secreting more insulin to maintain normal glucose — so fasting glucose can look perfectly normal while fasting insulin is already elevated. Optimal fasting insulin: 2-6 uIU/mL. A level above 10 uIU/mL with normal fasting glucose is a strong signal of early insulin resistance. This test costs less than $20 and is not included on any standard annual lab panel.

HOMA-IR

The Homeostatic Model Assessment of Insulin Resistance is calculated from fasting glucose and fasting insulin: (fasting glucose in mg/dL x fasting insulin in uIU/mL) divided by 405. A HOMA-IR above 1.9 suggests early insulin resistance; above 2.9 suggests significant resistance. I calculate HOMA-IR on every new patient because it gives a richer picture than either glucose or insulin alone.

HbA1c (Hemoglobin A1c)

HbA1c reflects average blood glucose over the prior 2-3 months by measuring the percentage of hemoglobin that has been glycated. Optimal for longevity: 4.8-5.2%. The ADA classifies 5.7-6.4% as prediabetes and above 6.5% as diabetes. But in longevity medicine, the goal is not to avoid prediabetes — it is to stay in the genuinely optimal range. Each 0.5% increase in HbA1c above 5.0% is associated with meaningful increases in cardiovascular and all-cause mortality risk, even within the “normal” range.

Triglycerides and Triglyceride/HDL Ratio

Fasting triglycerides above 100 mg/dL are a surrogate marker for VLDL overproduction — the hepatic output that rises with insulin resistance. The triglyceride/HDL ratio is a validated surrogate for insulin resistance and small dense LDL particle predominance: a ratio above 2.0 (using mg/dL units) identifies insulin-resistant physiology with approximately 70% sensitivity in non-diabetic adults. Optimal: triglycerides below 80 mg/dL, TG/HDL ratio below 1.5.

Key Takeaway: The full metabolic picture requires fasting glucose, fasting insulin, HbA1c, and a triglyceride/HDL ratio together. Any single marker in isolation can be normal while the others reveal significant insulin resistance. I have never seen a patient with all four of these in the optimal range who had clinically significant metabolic dysfunction.

Cardiovascular Biomarkers: Beyond the Standard Lipid Panel

Cardiovascular disease remains the leading cause of death in the developed world, yet the standard lipid panel misses a meaningful portion of high-risk individuals. These additional markers complete the picture:

ApoB (Apolipoprotein B)

The direct count of atherogenic lipoprotein particles in your blood. Optimal for longevity: below 60 mg/dL. More predictive of cardiovascular events than LDL-C in virtually every head-to-head study. Essential in any patient with elevated triglycerides, insulin resistance, or family history of premature cardiovascular disease. See our full ApoB guide for complete details.

Lp(a) — Lipoprotein(a)

Lp(a) is a genetically determined atherogenic lipoprotein that is neither reduced by statin therapy nor by lifestyle intervention. Elevated Lp(a) — above 50 mg/dL or 125 nmol/L — is present in approximately 20% of the population and independently doubles cardiovascular risk. Because Lp(a) is largely genetically fixed, it needs to be measured once, not repeatedly. Knowing your Lp(a) changes the risk equation: a patient with Lp(a) of 180 mg/dL should be treated with much lower ApoB targets than one with Lp(a) of 10 mg/dL.

hs-CRP (High-Sensitivity C-Reactive Protein)

CRP is an acute-phase reactant produced by the liver in response to systemic inflammation. The high-sensitivity assay detects chronic low-grade inflammation that standard CRP misses. Optimal: below 0.5 mg/L. A level of 1-3 mg/L doubles cardiovascular event risk independent of lipid levels (JUPITER trial, PMID: 18997196). Above 3 mg/L suggests chronic systemic inflammation requiring investigation — common drivers include visceral adiposity, periodontal disease, sleep apnea, gut dysbiosis, and chronic infections.

Homocysteine

Homocysteine is an amino acid intermediate that, when elevated (above 10 umol/L), independently damages endothelial cells, promotes thrombosis, and accelerates atherosclerosis. Elevation is most commonly caused by B12 deficiency, folate deficiency, low B6, or MTHFR genetic variants affecting methylation. It is directly modifiable with B-vitamin supplementation in most cases — making it one of the highest-yield correctable cardiovascular risk factors. Optimal: below 8 umol/L.

Oxidized LDL

Oxidized LDL (ox-LDL) is the form of LDL that initiates the atherosclerotic cascade — it is the particle that macrophages engulf to form foam cells and plaques. Elevated ox-LDL predicts atherosclerotic progression even in patients with normal LDL-C. It reflects both LDL particle number and oxidative stress. Reducing ox-LDL requires both reducing ApoB and reducing oxidative burden through antioxidant-rich diet, exercise, and inflammation control.

Hormonal Biomarkers: The Anabolic/Catabolic Balance

Hormonal decline begins in the third decade and accelerates through the fourth and fifth. Optimizing hormonal status is one of the highest-leverage longevity interventions because hormones regulate muscle mass, bone density, cognitive function, metabolic rate, immune function, and mood — all of which deteriorate with age at rates closely tied to hormonal levels.

Free Testosterone (Men and Women)

Total testosterone measures all testosterone in circulation — including the biologically inactive fraction bound to sex hormone-binding globulin (SHBG). Free testosterone measures the active fraction available to tissues. In men, free testosterone below 9 ng/dL is associated with loss of lean mass, decreased bone density, insulin resistance, depressed mood, and reduced exercise capacity. In women, free testosterone below 1.5 pg/mL can manifest as reduced libido, loss of muscle tone, fatigue, and cognitive changes. Optimal ranges require clinical interpretation by a physician familiar with hormonal medicine.

Free T3 and TSH (Thyroid)

TSH alone misses significant thyroid dysfunction — it measures the pituitary’s signaling, not the actual thyroid hormone available to your cells. Free T3 is the active thyroid hormone. Suboptimal free T3 (below 3.0 pg/mL) can produce symptoms of hypothyroidism — fatigue, weight gain, cold intolerance, constipation, elevated cholesterol — even with a normal TSH. See our full thyroid optimization guide for complete details on interpreting thyroid panels in the longevity context.

DHEA-S (Dehydroepiandrosterone Sulfate)

DHEA-S is the most abundant circulating steroid hormone and a precursor to sex hormones. It peaks in the mid-20s and declines 10-20% per decade thereafter. Low DHEA-S is associated with reduced lean mass, impaired immune function, increased cardiovascular risk, and accelerated cognitive decline. It is one of the most useful biological age markers — a 50-year-old with DHEA-S levels in the upper quartile for their age typically shows other markers of slower aging across multiple domains.

IGF-1 (Insulin-Like Growth Factor 1)

IGF-1 reflects growth hormone output and mediates most of growth hormone’s anabolic effects on muscle, bone, and connective tissue. Both very low IGF-1 (associated with reduced lean mass and bone density) and very high IGF-1 (potentially associated with cancer risk in some studies) are concerning. Optimal IGF-1 sits in the upper third of the age-adjusted reference range — roughly 150-250 ng/mL for most adults. IGF-1 optimization typically involves sleep quality, protein intake, and resistance training before any pharmacological consideration.

Morning Cortisol

The cortisol awakening response is a surrogate for HPA axis function. A blunted morning cortisol peak (below 10-12 ug/dL at 8am) can indicate adrenal fatigue, HPA axis dysregulation from chronic stress, or simply poor sleep. Elevated morning cortisol above 25 ug/dL persistently suggests chronic psychological stress, poor sleep quality, or subclinical Cushing’s physiology — each of which drives insulin resistance, muscle catabolism, and immune suppression.

Nutritional Biomarkers: The Deficiencies That Accelerate Aging

Nutritional deficiencies are common even in patients eating well-rounded diets, because soil depletion, gut absorption variability, genetic polymorphisms, and medication interactions all affect nutritional status independently of intake. These are the deficiencies I find most frequently and that produce the greatest impact when corrected:

25-OH Vitamin D

The most common clinically significant deficiency I see in practice. Vitamin D is not just a vitamin — it is a steroid hormone precursor that regulates over 2,000 genes involved in immune function, insulin sensitivity, muscle function, cancer suppression, and cardiovascular health. Optimal: 50-80 ng/mL (not the lab reference range of “above 30 ng/mL,” which was set to prevent rickets, not optimize health). I have seen measurable improvements in energy, immune resilience, and insulin sensitivity when patients move from 22 ng/mL to 65 ng/mL.

Omega-3 Index

The Omega-3 Index measures EPA plus DHA as a percentage of total red blood cell fatty acids. An index below 4% is associated with nearly triple the sudden cardiac death risk compared to an index above 8%. Most Americans sit at 4-5%. Optimal for longevity: above 8%. Achieving this typically requires either significant fatty fish consumption (3-4 servings per week of sardines, mackerel, salmon) or high-quality omega-3 supplementation at meaningful doses (2-4g EPA+DHA daily). This test is not on any standard panel and is ordered specifically.

RBC Magnesium

Standard serum magnesium is largely useless — only 1% of total body magnesium circulates in serum, and the body tightly defends serum levels at the expense of intracellular stores. RBC magnesium measures the intracellular compartment and detects functional deficiency that serum testing misses. Magnesium deficiency is implicated in insulin resistance, hypertension, muscle cramping, cardiac arrhythmia, anxiety, poor sleep, and migraine. Approximately 50% of Americans are functionally magnesium insufficient by RBC standards. Optimal RBC magnesium: 5.2-6.5 mg/dL.

B12 and Methylmalonic Acid (MMA)

Serum B12 can appear normal while functional B12 deficiency exists at the cellular level. Methylmalonic acid (MMA) is the most sensitive functional marker of B12 sufficiency — elevated MMA indicates cellular B12 deficiency even when serum B12 is within range. B12 deficiency causes peripheral neuropathy, megaloblastic anemia, cognitive impairment, and elevated homocysteine. Metformin, proton pump inhibitors, and age-related gastric atrophy are the most common causes of functional B12 depletion in my patient population.

Key Takeaway: The nutritional deficiencies most relevant to aging — vitamin D, omega-3s, magnesium, B12 — are all missed by standard annual labs. Each is correctable with targeted supplementation once identified. The cost of testing these markers is less than most copays. The downstream benefit of correcting them can be substantial.

Functional Biomarkers: What Your Body Can Actually Do

Blood and urine markers tell you about chemistry. Functional markers tell you about capacity — the actual performance of your cardiovascular, musculoskeletal, and neurological systems. These are among the strongest predictors of healthspan and longevity in the literature:

VO2max

VO2max — the maximum rate of oxygen consumption during maximal exercise — is the single strongest predictor of all-cause mortality in otherwise healthy individuals. A 2018 study of 122,000 patients found that low cardiorespiratory fitness was associated with a higher mortality risk than smoking, hypertension, or diabetes (PMID: 30418580). Moving from “low” to “below average” fitness reduces all-cause mortality risk by 50%. VO2max is measured by formal exercise testing or estimated from a 1-mile walk test or Cooper 12-minute run. Optimal for a 50-year-old man: above 42 mL/kg/min. For a 50-year-old woman: above 37 mL/kg/min.

Grip Strength

Grip strength measured by hand dynamometry is one of the most validated functional longevity markers. A meta-analysis of 42 studies found that each 5 kg decrease in grip strength was associated with a 16% increase in all-cause mortality, a 17% increase in cardiovascular mortality, and a 9% increase in stroke risk (PMID: 25982160). Grip strength reflects total lean mass, neural drive, and systemic anabolic status — it is a proxy for the overall musculoskeletal reserve that protects against frailty. Optimal for men 50-59: above 44 kg. For women 50-59: above 27 kg.

HRV (Heart Rate Variability)

HRV is the functional measure of autonomic nervous system flexibility — the degree to which your parasympathetic system can rapidly modulate cardiac output. Chronically low HRV predicts all-cause mortality, cardiovascular disease, metabolic dysfunction, and reduced cognitive resilience. See our complete HRV guide for measurement methodology, age-referenced benchmarks, and the six evidence-based interventions that raise it. HRV measured with a modern wearable (WHOOP, Oura, Garmin, Polar H10) is the most accessible and actionable functional longevity biomarker available to patients outside of a clinical setting.

Single-Leg Balance Test

The ability to stand on one leg with eyes closed for 10 seconds is a simple but surprisingly powerful longevity predictor. A 2023 study in the British Journal of Sports Medicine found that inability to perform this test was associated with an 84% higher risk of all-cause mortality over a 7-year follow-up period, independent of age, sex, BMI, and comorbidities (PMID: 35173011). Balance depends on cerebellar function, proprioception, vestibular processing, and core strength — all of which decline with aging and can be trained. I do this test at baseline on every patient.

How to Order a Longevity Biomarkers Panel

The full longevity panel described in this article is not available as a single order from any standard lab. It is assembled from individual test orders across several categories. Here are your options:

Through a Functional Medicine Physician

The most comprehensive approach. A functional medicine physician who specializes in longevity can order the full panel, interpret results in clinical context, and build an intervention plan based on your specific findings. In our practice, the initial longevity evaluation includes a complete panel review, functional assessment, and a personalized optimization protocol. This is the approach I recommend for anyone serious about proactive health management.

Direct-to-Consumer Lab Services

Services like Quest Diagnostics (QuestDirect), LabCorp OnDemand, Ulta Lab Tests, and Let’s Get Checked allow individuals to order many of these markers without a physician order. Costs are generally $15-$50 per marker. Function Health and Lifeforce offer curated longevity panels that cover most of the markers described here for approximately $500-$800. These are useful for motivated patients who want data before or between physician visits.

What to Ask Your Primary Care Physician

If you prefer to work through your existing physician, bring a specific list. Ask for: fasting insulin (in addition to fasting glucose), ApoB, Lp(a), hs-CRP, homocysteine, 25-OH vitamin D, omega-3 index, RBC magnesium, free T3 (in addition to TSH), and DHEA-S. Many PCPs will order these if the patient specifically requests them and explains the clinical rationale. Some will need to be ordered as out-of-pocket tests if insurance does not cover them.

Frequently Asked Questions

How often should I run a longevity biomarkers panel?

For initial assessment: run the full panel once to establish your personal baseline. For ongoing monitoring: I recommend running the metabolic, cardiovascular, hormonal, and nutritional labs annually, with more frequent monitoring (every 3-6 months) for any marker that is significantly out of range until it is corrected. Functional markers (VO2max, grip strength, balance) can be assessed every 6-12 months. Some markers — like Lp(a) — are genetically fixed and only need to be measured once.

What does a longevity biomarkers panel cost?

Through a functional medicine practice, a comprehensive longevity panel typically costs $400-$1,200 including the physician interpretation and follow-up. Direct-to-consumer services like Function Health offer panels covering 100+ markers for approximately $500/year. Individual markers ordered a la carte through Quest or LabCorp typically run $15-$50 each, so a targeted panel of 15-20 markers can be assembled for $300-$600 out of pocket. Many markers are covered by insurance when ordered with clinical indication.

Can a longevity panel predict how long I will live?

No longevity panel predicts lifespan with individual precision — biology is too variable and too context-dependent. What it can do is identify your current biological age relative to your chronological age, quantify your modifiable risk factors, and provide a roadmap for reducing your risk of the diseases and functional declines that most commonly shorten healthspan. Think of it as a risk stratification tool and intervention guide, not a fortune-telling exercise.

Is a longevity panel different from a biological age test?

Biological age tests — including epigenetic clock assays like Horvath’s clock, GrimAge, and DunedinPACE — measure DNA methylation patterns to estimate biological age independent of chronological age. These are powerful research tools that are now available to consumers through companies like TruDiagnostic. They complement but do not replace a functional longevity panel — epigenetic clocks tell you where you are on the aging curve, while functional and biochemical markers tell you which levers to pull to move that curve.

The Bottom Line

The standard annual physical gives you a snapshot of whether you have a diagnosable disease today. The longevity biomarkers panel gives you a complete picture of where your biology is headed — and, critically, what you can do to change its trajectory. The markers described in this article cover metabolic health, cardiovascular risk, hormonal optimization, nutritional sufficiency, and physical capacity. Together, they constitute a functional biological age assessment. None of them are exotic or experimental — they are standard assays available at any reference lab. The only thing standing between most people and this level of information is knowing what to ask for. Now you do. If you want help interpreting your results and building a personalized longevity protocol, that is exactly what we do in our functional medicine practice.

Sources

Mandsager K, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open. 2018;1(6):e183605. PMID: 30418580
Leong DP, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273. PMID: 25982160
Araujo CG, et al. Ability to sit and rise from the floor as a predictor of all-cause mortality. European Journal of Preventive Cardiology. 2014;21(7):892-898. PMID: 24242282
Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine. 2008;359(21):2195-2207. PMID: 18997196
Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573-591. PMID: 29676998
Criqui MH, et al. Lipoprotein(a) and cardiovascular risk prediction. JAMA. 2022;326(2):173-174. PMID: 35819420

Ready for a Complete Longevity Biomarkers Evaluation?

Our longevity medicine evaluation covers all five domains — metabolic, cardiovascular, hormonal, nutritional, and functional — and delivers a personalized biological age assessment with a prioritized action plan. Dr. Biernacki reviews every marker in the context of your clinical history and builds an intervention protocol tailored to your specific findings and goals.

Book a Longevity Biomarkers Evaluation